| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Review |
| Article Title |
Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Henrique Souza-Tavares, Carolline Santos Miranda, Isabela Macedo Lopes Vasques-Monteiro, Cristian Sandoval, Daiana Araujo Santana-Oliveira, Flavia Maria Silva-Veiga, Aline Fernandes-da-Silva and Vanessa Souza-Mello |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brazil) |
303785/2020–9 |
| Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro |
E-26/200.984/2022 |
|
| Corresponding Author |
Vanessa Souza-Mello, PhD, Associate Professor, Department of Anatomy, Rio de Janeiro State University, Blvd. 28 de setembro 87, fundos, Rio de Janeiro 20551030, Brazil. souzamello.uerj@gmail.com |
| Key Words |
Obesity; Insulin resistance; Peroxisome proliferator-activated receptors; Pancreas; Hepatic steatosis; Adipose tissue |
| Core Tip |
The world faces a pandemic of obesity and metabolic diseases. Peroxisome proliferator-activated receptors’ (PPARs’) target genes regulate several metabolic pathways, alleviating obesity and its metabolic impairments. PPARα exerts relevant anti-inflammatory, anti-steatotic, and pro-thermogenic effects, collaborating with weight loss and insulin resistance alleviation. PPARγ is useful for glycemic management, albeit with caution due to side effects after its total activation. PPARβ/δ is not clinically used owing to a pro-tumorigenic profile. However, Pan-PPAR or dual-PPAR agonists can retain PPARβ/δ or partial PPARγ activation benefits and configure promising approaches to treat metabolic diseases alone or in combination with other drug classes. |
| Publish Date |
2023-07-10 08:58 |
| Citation |
Souza-Tavares H, Miranda CS, Vasques-Monteiro IML, Sandoval C, Santana-Oliveira DA, Silva-Veiga FM, Fernandes-da-Silva A, Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas. World J Gastroenterol 2023; 29(26): 4136-4155 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i26/4136.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i26.4136 |
